HZNP Horizon Therapeutics Public Ltd Co

Price (delayed)

$87.93

Market cap

$19.76B

P/E Ratio

66.61

Dividend/share

N/A

EPS

$1.32

Enterprise value

$21.53B

Sector: Healthcare
Industry: Drug Manufacturers - General

Highlights

HZNP's gross profit has soared by 64% year-on-year
Horizon Therapeutics's revenue has soared by 59% YoY
The equity has soared by 76% year-on-year but it is down by 4.2% since the previous quarter
The company's debt has surged by 157% QoQ and by 90% YoY
The stock's price to earnings (P/E) is 82% more than its last 4 quarters average of 36.6

Key stats

What are the main financial stats of HZNP
Market
Shares outstanding
224.77M
Market cap
$19.76B
Enterprise value
$21.53B
Valuations
Price to earnings (P/E)
66.61
Price to book (P/B)
5.11
Price to sales (P/S)
9
EV/EBIT
67.51
EV/EBITDA
35.67
EV/Sales
9.84
Earnings
Revenue
$2.19B
EBIT
$318.89M
EBITDA
$603.42M
Free cash flow
$550.77M
Per share
EPS
$1.32
Free cash flow per share
$2.46
Book value per share
$17.21
Revenue per share
$9.77
TBVPS
$15.9
Balance sheet
Total assets
$7.85B
Total liabilities
$3.99B
Debt
$2.58B
Equity
$3.85B
Working capital
$1.06B
Liquidity
Debt to equity
0.67
Current ratio
2.37
Quick ratio
1.63
Net debt/EBITDA
2.92
Margins
EBITDA margin
27.6%
Gross margin
75.5%
Net margin
12.8%
Operating margin
16.1%
Efficiency
Return on assets
4.6%
Return on equity
8%
Return on invested capital
12.5%
Return on capital employed
4.5%
Return on sales
14.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HZNP stock price

How has the Horizon Therapeutics stock price performed over time
Intraday
-2.17%
1 week
-7.07%
1 month
-0.86%
1 year
109.21%
YTD
20.21%
QTD
-4.47%

Financial performance

How have Horizon Therapeutics's revenue and profit performed over time
Revenue
$2.19B
Gross profit
$1.65B
Operating income
$352.67M
Net income
$280.04M
Gross margin
75.5%
Net margin
12.8%
The company's operating margin has surged by 99% YoY but it fell by 28% QoQ
The company's net margin has shrunk by 70% YoY and by 28% QoQ
HZNP's gross profit has soared by 64% year-on-year
Horizon Therapeutics's revenue has soared by 59% YoY

Growth

What is Horizon Therapeutics's growth rate over time

Valuation

What is Horizon Therapeutics stock price valuation
P/E
66.61
P/B
5.11
P/S
9
EV/EBIT
67.51
EV/EBITDA
35.67
EV/Sales
9.84
The stock's price to earnings (P/E) is 82% more than its last 4 quarters average of 36.6
Horizon Therapeutics's EPS has plunged by 59% YoY and by 31% from the previous quarter
The equity has soared by 76% year-on-year but it is down by 4.2% since the previous quarter
HZNP's price to book (P/B) is 70% higher than its 5-year quarterly average of 3.0 and 14% higher than its last 4 quarters average of 4.5
HZNP's price to sales (P/S) is 125% more than its 5-year quarterly average of 4.0 and 11% more than its last 4 quarters average of 8.1
Horizon Therapeutics's revenue has soared by 59% YoY

Efficiency

How efficient is Horizon Therapeutics business performance
HZNP's ROE has plunged by 75% YoY and by 37% from the previous quarter
Horizon Therapeutics's return on assets has shrunk by 68% YoY and by 39% QoQ
HZNP's return on invested capital is down by 47% since the previous quarter
Horizon Therapeutics's ROS has decreased by 30% from the previous quarter

Dividends

What is HZNP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HZNP.

Financial health

How did Horizon Therapeutics financials performed over time
The total assets is 97% more than the total liabilities
The company's total liabilities has surged by 95% QoQ and by 88% YoY
The total assets has soared by 82% YoY and by 29% from the previous quarter
The company's debt is 33% lower than its equity
The debt to equity has surged by 168% since the previous quarter and by 8% year-on-year
The company's debt has surged by 157% QoQ and by 90% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.